Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-tobacco nicotine use and the risk of cataract development.

Annals of epidemiology·2026
Same author

Anterior Lens Subluxation and Pseudohypopyon.

Case reports in ophthalmological medicine·2026
Same author

Prevalence and incidence of mental health disorders in patients with inherited retinal diseases: a population-based study.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2026
Same author

Transient Pourfour du Petit Syndrome as the Presenting Sign of Internal Carotid Artery Aneurysm.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Morphologic Changes of Macular Choroidal Neovascularization on OCT Angiography Following Faricimab Therapy in Patients With AMD.

Journal of vitreoretinal diseases·2026
Same author

Risk of diabetic retinopathy progression after YAG laser capsulotomy.

Journal of cataract and refractive surgery·2026

Related Experiment Video

Updated: Sep 16, 2025

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K

DOCETAXEL-INDUCED PIGMENTARY MACULOPATHY.

Henry C Skrehot1, Amer Alsoudi2, Emmanuel Y Chang3

  • 1School of Medicine, Baylor College of Medicine, Houston, TX.

Retinal Cases & Brief Reports
|July 8, 2025
PubMed
Summary
This summary is machine-generated.

Docetaxel can cause vision problems like pigmentary maculopathy. Stopping this chemotherapy drug led to improved vision in a patient with prostate cancer.

Keywords:
docetaxeldrug toxicitypigmentary maculopathytaxanetoxic maculopathy

More Related Videos

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.6K
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
09:24

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration

Published on: March 10, 2023

1.8K

Related Experiment Videos

Last Updated: Sep 16, 2025

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

3.6K
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
09:24

A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration

Published on: March 10, 2023

1.8K

Area of Science:

  • Ophthalmology
  • Oncology
  • Toxicology

Background:

  • Docetaxel is a chemotherapy agent used for prostate cancer.
  • Ocular side effects of docetaxel are rare but can be serious.
  • Pigmentary maculopathy is a condition affecting the macula, potentially causing vision loss.

Purpose of the Study:

  • To document a case of bilateral docetaxel-induced pigmentary maculopathy.
  • To highlight the visual consequences of docetaxel treatment.

Main Methods:

  • A 79-year-old male with prostate cancer received docetaxel.
  • The patient experienced blurred vision and was diagnosed with bilateral macular hyperpigmentation.
  • Docetaxel was discontinued based on suspected toxicity.

Main Results:

  • The patient's best corrected visual acuity (BCVA) decreased significantly after docetaxel initiation.
  • Fundoscopic examination revealed bilateral central macular hyperpigmentation.
  • Following docetaxel cessation, BCVA improved, and fundoscopic findings stabilized.

Conclusions:

  • Docetaxel can induce pigmentary maculopathy in adult patients.
  • Early detection and discontinuation of docetaxel are crucial for visual recovery.
  • This case underscores the importance of monitoring ocular health during docetaxel therapy.